Covid-19: tech companies’ solidarity boosts innovative research at Nantes university hospital

In Atlantic France, companies mostly belonging to the digital sector raised more than €130,000 to support Nantes university hospital. The emergency fund will be used to accelerate key medical R&D projects tackling the coronavirus pandemic.

The goal was ambitious: raise €100,000 in less than a week. The fundraising backed by major tech companies from Atlantic France (Intuiti, iAdvize, Akeneo, Lengow, BeApp, EP, 10-Vins…) has been a success, with 492 donators and €133,719 collected. 

The money will go to the Covid-19 emergency fund created by Nantes university hospital, which will be used for important research projects aiming to have a global impact on the coronavirus pandemic.

Coronado: studying how vulnerable diabetes patients are to coronavirus

The name of the national R&D project CORONADO stands for CORONAvirus disease 2019 and Diabetes Outcomes. Launched in partnership with the Société francophone du Diabète and the French Federation of diabetics, it aims to better understand the unfavorable prognosis of people with diabetes when facing the SARS-CoV-2. 

AziA and Discovery: testing treatments against Covid-19

The AziA therapeutic trial compares two combinations of antibiotics in the treatment of patients with Covid-19 pneumonia. The Nantes university hospital also takes part in the European clinical study, Discovery, which compares four medical treatments against coronavirus.

MICI-Covid and Ibis Covid biocollections: understanding knock-on effects of other diseases

The treatment of a chronic Inflammatory Bowel Disease (IBD, MICI in French) could lead to a risk of Covid-19 infection. The objective of MICI-Covid biocollection is to better understand the effects of these therapies in order to minimise risks during the pandemic. On the other hand, the Ibis Covid biocollection aims to study the relation between the immune response and its clinical consequences.